Business
Neurochem announces important initiatives to provide medical and health benefits to patients
Neurochem will host a live web conference today November 8, 2007, at 8:30 AM ET LAVAL, QC, Nov. 8...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nNeurochem will host a live web conference today November 8, 2007, at\n\n\n8:30 AM ET\n\n\nLAVAL, QC, Nov. 8 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM)\nannounces today important initiatives including the expansion of its product\ncandidate portfolio, the refocusing of its proprietary R&D assets and the\nexpected reduction of its burn rate compared to fiscal 2007. As part of these\ninitiatives, Neurochem is:\n\n\n- Moving its next generation lead candidate NRM-8499 into preclinical\n development for the treatment of Alzheimer's disease (AD) and is also\n announcing the early termination of its European Phase III clinical\n trial for tramiprosate (ALZHEMED(TM)).\n- Taking steps, in light of promising results from preliminary post-hoc\n analysis of the data from the North American Phase III trial for\n tramiprosate, to commercialize this product as a branded nutraceutical,\n starting as early as 2008.\n- Continuing to advance its programs for Amyloid A (AA) amyloidosis as\n well as for Diabetes Type II/features of metabolic syndrome.\n\n"Our goal is to provide innovative health solutions to patients suffering\nfrom serious diseases as soon as possible," said Dr. Francesco Bellini,\nChairman, President and CEO of Neurochem. "With the strategy unveiled today,\nthe Company plans to make tramiprosate available to consumers. As well,\nNeurochem is confirming its commitment to developing new drugs for AD by\nadvancing into preclinical development a prodrug which improves tramiprosate\nconcentration in the brain several fold, thus leveraging the wealth of\nknowledge the Company has gained from the work accomplished to date in this\nfield. Neurochem will be dedicating its resources to building a strong and\ndiversified pipeline of product candidates, which could potentially provide\ncash flow in the near term. As a result, our business model is expanding\nbeyond the traditional biopharmaceutical strategy to one that embraces shorter\nterm projects. These projects should fund research and development activities,\nwhile complementing our longer term prescription drug programs geared at\nsustaining the Company's future growth," he concluded.\n\nSeeking Medical and Health Benefits in Significant Therapeutic Areas\n\nAlzheimer's disease - Next Generation - Tramiprosate (ALZHEMED(TM))\n----------------...